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Abstract
Introduction: Traumatic brain injury (TBI) is associated with a profound immunological dysfunction manifested by
a severe shift from T-helper type 1 (Th1) to T-helper type 2 (Th2) response. This predisposes patients to infections,
sepsis, and adverse outcomes. Probiotic bacteria have been shown to balance the Th1/Th2 cytokines in allergic
murine models and patients. For the present study, we hypothesized that the enteral administration of probiotics
would adjust the Th1/Th2 imbalance and improve clinical outcomes in TBI patients.
Methods: We designed a prospective, randomized, single-blind study. Patients with severe TBI and Glasgow Coma
Scale scores between 5 and 8 were included, resulting in 26 patients in the control group and 26 patients in the
probiotic group. All patients received enteral nutrition via a nasogastric tube within 24 to 48 hours following
admission. In addition, the probiotic group received 10
9 bacteria of viable probiotics per day for 21 days. The
associated serum levels of Th1/Th2 cytokines, Acute Physiology and Chronic Health Evaluation (APACHE) II and
Sequential Organ Failure Assessment (SOFA) scores, nosocomial infections, length of ICU stay, and 28-day mortality
rate were studied.
Results: The patients responded to viable probiotics, and showed a significantly higher increase in serum IL-12p70
and IFNg levels while also experiencing a dramatic decrease in IL-4 and IL-10 concentrations. APACHE II and SOFA
scores were not significantly affected by probiotic treatment. Patients in the probiotic group experienced a
decreased incidence of nosocomial infections towards the end of the study. Shorter ICU stays were also observed
among patients treated with probiotic therapy. However, the 28-day mortality rate was unaffected.
Conclusions: The present study showed that daily prophylactic administration of probiotics could attenuate the
deviated Th1/Th2 response induced by severe TBI, and could result in a decreased nosocomial infection rate,
especially in the late period.
Trial registration: ChiCTR-TRC-10000835.
Introduction
Traumatic brain injury (TBI) is associated with pro-
found immunological dysfunction. Severe immunode-
pression involving the cell-mediated immune response
may occur early and may even last for several weeks [1].
In addition, hyperinflammation may also occur as a
result of injury. This can be attributed to the production
of glucocorticoids after brain injury, which inhibits the
production of IL-12, a cytokine secreted by monocytes/
macrophages and dendritic cells (DCs). IL-12 plays a
critical role in driving naive CD4
+ T-helper cells (Th0)
to T-helper type 1 (Th1) subtypes, directly contributing
to impaired cellular immunity [2]. IL-4 and IL-10, two
anti-inflammatory T-helper type 2 (Th2) cytokines
known for their ability to suppress the production of
IFNg and IL-2 by Th1 cells [3], appear in high
* Correspondence: zhujingci2009@163.com
2School of Nursing, Third Military Medical University, 30 Gaotanyan Street,
Chongqing 400038, China
Full list of author information is available at the end of the article
Tan et al. Critical Care 2011, 15:R290
http://ccforum.com/content/15/6/R290
© 2011 Tan et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.concentrations within hours following the brain injury
[2,4,5]. An obvious shift from Th1 response to Th2 is
presented, and renders patients more vulnerable to
infections, sepsis, and adverse outcomes [4,5]. The inci-
dence of ventilator-associated pneumonia (VAP) can
reach 60% in this category of patients [2]. When we
manage postinjury infectious complications with antibio-
tics, therefore, it is believed that some therapeutic stra-
tegies aimed at enhancing intrinsic immune functions
are also needed. In particular, the rapid emergence of
antibiotic-resistant pathogens as well as the lack of new
antimicrobial agents needs to be taken into account in
the near future [6,7].
Probiotics have increasingly been shown to manage
various infectious diseases due to their ability to restore
the nonpathogenic digestive flora that commonly disap-
pear as a result of various diseases or following medical
treatment with pharmaceuticals such as antibiotics [8].
Research indicates that probiotics reduce the growth of
potentially pathogenic microorganisms, improve gut
mucosal barrier function, and modulate local and sys-
temic immune functions [9]. Data support the use of
probiotics as a treatment for infectious diarrhea, antibio-
tic-associated diarrhea, and necrotizing enterocolitis [9].
However, the results of limited studies that focused on
critically ill patients remain controversial.
Two recent meta-analysis of probiotics in critically ill
patients achieved different conclusions: one demon-
strated the efficacy of probiotics on the incidence of
VAP [10], while the other concluded that probiotics had
no effects on these patients [11]. Schultz and Haas
e x p l a i n e dt h a tt h et w of o l l o wing reasons might contri-
bute to the difference between the two meta-analysis
[12]: first, the meta-analysis that achieved negative
results included trials of postoperative patients who are
often admitted to the ICU for too short a stay to
develop VAP [11]; and second, this meta-analysis did
not include one important trial that showed a reduced
rate of VAP with probiotics [13]. Morrow and Kollef
concluded that much of the current confusion sur-
rounding the efficacy of probiotics stemmed from the
heterogeneity of study populations, differences in study
designs, inconsistencies in the strains used, and the lim-
ited understanding of probiotics’ mechanisms of action
[14]. Although the immunomodulatory effects of probio-
tics have been studied widely in vitro and in animal
models [15], it is difficult to extrapolate the results of
animal studies to human populations. More well-
designed studies are therefore recommended that incor-
porate both clinical outcomes and measurement of bio-
markers putatively related to clinical effects such as
immune markers, changes in the microbiota, and gut
barrier function, in order to generate data that achieve
more consistent evidence [9].
To date, no study has focused on the effects of pro-
biotics in severe traumatic brain-injured patients who
are at extremely high risk of VAP. We therefore con-
ducted a prospective randomized trial to investigate the
influence of probiotics on this specific category of
patients. The primary endpoint was to determine
whether and to what extent probiotics affect the Th1/
Th2 cytokines. Our secondary endpoints were the infec-
tion rate, use of antibiotics, ICU length of stay, and 28-
day mortality rate.
Materials and methods
The present study was conducted between October 2009
and January 2011 at the Affiliated Hospital of North
Sichuan Medical College (Nanchong, Sichuan, China), in
a six-bed specialized ICU in the Department of Neuro-
surgery. The study protocol was approved by the
Human Ethics Committee of the hospital (AHNSMC,
2009066) and was performed in compliance with the
Helsinki Declaration. Due to the unconsciousness of
patients, informed consent was obtained from their clo-
sest family members prior to their admittance into the
study. Further consent was not obtained from patients
after they recovered, as this was not required by the
Human Ethics Committee.
The following inclusion criteria were applied to
patients: closed head injury alone; admission within 24
hours after trauma; a Glasgow Coma Scale score
between 5 and 8; aged 18 to 60 years old; and able to be
fed via nasogastric tube within 48 hours after admission.
Exclusion criteria were: previous significant digestive,
hematological, and endocrine diseases; immunosuppres-
sion; presence of pneumonia or other infectious diseases
upon admission; HIV-positive; other associated trauma
such as extremity fractures and chest or abdominal
trauma; cancer; pregnancy, or lactation; and obesity
(body mass index > 30) or malnutrition (body mass
index < 18.5).
After inclusion (which was done within 48 hours after
admission), patients were randomized with a ratio of 1:1
into the probiotic group or the control group. Randomi-
zation was done with a computer-generated random
number and sealed envelopes kept by a person not
involved in the investigation. The enrolled patients,
those who processed samples, and the bedside nurses in
the research unit were blind to the study design. The
investigators as well as the physicians in charge knew
whether or not the patient had received probiotics.
All patients received enteral nutrition (EN) (3.8 g pro-
tein, 13.8 g carbohydrate, 3.4 g fat/100 ml, osmolarity
250 mOsm/l, no fibers; Ruisu, Huarui Pharmaceutical
Co., Ltd, Beijing, China) within 48 hours following hos-
pital admission by nasogastric tube, starting at 10 kcal/
kg/day and gradually increasing to an energy target of
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day on day 3. A rate of 25 ml/hour was initiated and
then increasingly progressed by 25 ml/hour every 4
hours until a goal of 125 ml/hour was achieved. If the
gastric residual volumes exceeded 150 ml after a second
check using a 60-ml syringe, prokinetic agents were
initiated and feeds were resumed and advanced until the
goal rate was achieved. If the patient was unable to
meet the energy goal after 5 days by enteral route alone,
a supplementation of parenteral nutrition was initiated.
If the patient transitioned to parenteral nutrition and
could not resume enteral feeding for more than 2 days,
the study was discontinued prematurely.
The probiotic group received seven sachets of viable
probiotics three times a day, at 7:00, 15:00, and 23:00
hours, providing a total of 10
9 bacteria. Each sachet of
probiotics (Golden Bifid, Shuangqi Pharmaceutical Co.,
Ltd, Inner Mongolia, China) contained 0.5 × 10
8 Bifido-
bacterium longum,0 . 5×1 0
7 Lactobacillus bulgaricus,
and 0.5 × 10
7 Streptococcus thermophilus. The probiotics
were dissolved in 20 ml sterilized distilled water and
administered through a nasogastric tube for 21 consecu-
tive days. Pre and post administration of the drug, an
additional 40 to 60 ml sterile water was given to flush
the tube. When patients started oral intake and the
nasogastric tube was removed, probiotics were ingested
orally for the remaining days. Study participants were
not allowed to use any other product containing probio-
tics during the trial. Another conventional therapy for
these patients included operation when necessary, anti-
biotics, using mannitol to reduce intracranial pressure
and oxygen absorption, and so forth. Tracheotomy was
performed when patients presented complications
related to dyspnea or hypoxemia, produced too much
thick sputum to aspirate via nasal suctioning, or were
expected to remain in a long period of coma. Intrave-
nous pantoprazole (40 mg/day) was administered as a
stress ulcer prophylaxis (generally for 3 to 4 days from
admission) if deemed necessary by the attending
physician.
Samples for complete blood count, blood gases, liver
and renal function, and C-reactive protein (CRP) were
collected in the morning on days 1 (before the initiation
of EN), 4, 8, 15, and 21, and were analyzed at the hospi-
tal clinical chemistry laboratory. Combined with clinical
data recorded by nurses and physicians in charge, the
Acute Physiologic Chronic Health Evaluation (APACHE)
II scores as well as the Sequential Organ Failure Assess-
ment (SOFA) scores were evaluated [16,17]. The day
when EN initiated was designated day 1. Serum samples
separated from the whole blood by centrifugation were
also collected at the same time points and were stored
at -80°C until cytokine analysis was performed. Sera
from 20 age-matched and sex-matched healthy
volunteers were collected to serve as normal controls.
Serum levels of IL-12p70, IL-4, IL-6, IL-10 and IFNg
were determined using the human ELISA kits of R&D
Systems, Inc. (Minneapolis, MN, USA) according to
instructions given by the manufacturer. All determina-
tions were performed in duplicate and the mean of two
observations was applied. The minimum detectable
doses of IL-12p70, IL-4, IL-6, IL-10 and IFNg with these
assay kits were 15, 4, 1, 4 and 4 pg/ml, respectively.
Nosocomial infections were prospectively recorded by
the physicians in charge of the patient according to the
Centers for Disease Control and Prevention criteria [18].
Specifically, VAP was defined as pneumonia occurring
more than 48 hours after endotracheal intubation, and
was diagnosed by the presence of both a new or pro-
gressive radiographic infiltrate plus at least two clinical
features - fever > 38.0°C, leucocytosis (white blood cells
count > 12 × 10
9/l), leucopenia (white blood cells count
<4×1 0
9/l), or purulent tracheobronchial secretions -
and positive semiquantitative cultures of tracheobron-
chial secretions [19]. Surveillance cultures of tracheo-
bronchial secretions were taken once or twice weekly
depending on patients’ clinical symptoms. Multiple
infections in the same patient were deemed to be one
endpoint. The use of antibiotics, the ICU length of stay,
as well as the 28-day mortality rate were also recorded.
The ICU length of stay was defined as the number of
days from the day that EN started to the discharge of
the patient from the ICU.
Statistical analysis
Because no previous study had examined the effect of
probiotics in this context, we estimated that a sample
size of 40 patients would be sufficient for this study.
Based on previous experiences and studies, it was esti-
mated that there would be a 30% dropout after rando-
mization. We aimed to recruit 52 patients in total and
analyze data per protocol as well as by intention to
treat. Per-protocol analysis was interpreted to include
only patients who participated in the trial for 21 days.
T h ed a t aw e r ea n a l y z e du s i n gt h es t a t i s t i c a ls o f t w a r e
p r o g r a mS P S S1 1 . 5( S P S SI n c . ,C h i c a g o ,I L ,U S A ) .T h e
Shapiro-Wilk test was used to assess whether continuous
data were normally distributed. For continuous variables,
differences between groups were tested with Student’s t
test or analysis of variance for normally distributed data
or the Mann-Whitney U test for non-normally distribu-
ted data. Comparisons of categorical data were done by
c h i - s q u a r e dt e s to rF i s h e r ’se x a c tt e s t .T w o - s i d e dP <
0.05 was considered statistically significant.
Results
During the 15-month study period, 137 patients were
assessed for eligibility and 52 were enrolled. After
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on days 4, 3, and 16, respectively; five of the controls died
on days 24, 10, 10, 10, and 4, respectively; and two patients
(one in each group) were predischarged from hospital on
days 13 and 15 due to financial reasons. Except for the
three patients who died within the first 4 days after the
initiation of EN, all patients (100%) in the probiotic group
and 80% of the patients in the control group were fed
mainly via the enteral route by day 7 (P = 0.066). No
patients stopped EN for more than 2 consecutive days.
Thus, 43 patients successfully completed the 21-day study
and were included in the per-protocol analysis (Figure 1).
There were no differences in baseline characteristics
between groups (Table 1). Intention-to-treat and per-pro-
tocol analyses yielded similar results and thus only results
of the former are shown here.
Immune variables
As expected, the patients’ serum levels of IL-12p70
and IFNg were significantly lower than those of
normal controls throughout the study period and
reached a nadir on day 8, whereas the concentrations
of IL-4 and IL-10 exhibited an opposite tendency. On
day 15, however, the patients who received probiotics
showed higher levels of IL-12p70 than did the control
patients (P = 0.042). On day 21, significantly higher
increases of both IL-12p70 and IFNg were observed in
the probiotic group compared with those of the con-
trol group (P =0 . 0 2 3a n dP = 0.017, respectively).
Interestingly, the probiotic group exhibited signifi-
cantly lower levels of IL-4 and IL-10 than the control
group on day 21 (P = 0.017 and P = 0.027, respec-
tively), and appeared to have similar IL-4 concentra-
tions to the normal controls (P = 0.06). With respect
to IL-6 and CRP, all patients demonstrated an early
increase after injury and reached a peak on day 4 with
the following decreasing tendencies: significantly lower
levels were found among patients who received pro-
biotics compared with patients in the control group
on day 15 (P = 0.034 and P = 0.039, respectively) and
Total randomized 
n=52 
Probiotic group 
n=26 
Control group 
n=26 
Not completed the trial n=4 
P P   a n a l y s i s         n = 2 2  
Not completed the trial n=5 
P P   a n a l y s i s         n = 2 1  
ITT analysis 
Assessed for eligibility 
n=137 
Excluded n=85 
Could not initiate EN within 48 h 
following admission n=23 
Did not need EN n=31 
Other exclusion criteria n=19 
Patient consent not obtained n=12 
Figure 1 CONSORT flow diagram of the trial. EN, enteral nutrition; ITT, intention to treat; PP, per protocol.
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Page 4 of 10on day 21 (P = 0.042 and P = 0.016, respectively) (Fig-
ures 2 and 3).
Clinical outcomes
During the study period, 24 patients developed infec-
tions and no significant differences were found between
groups (34.6% vs. 57.7%, P = 0.095). VAP was diagnosed
in seven (43.8%) of the 16 patients in the probiotic
group and in 13 (68.4%) of the 19 in the control group
receiving endotracheal incubation and mechanical venti-
lation. In the other patients not mechanically ventilated,
two in the probiotic group and one in the control group
developed pneumonia. One of the 13 patients who
acquired VAP and another one in the control group
developed urinary tract infection (Table 2). The species
of organisms isolated on tracheobronchial secretions
cultures in patients with VAP are shown in Table 3. All
patients acquired pathogens and presented VAP within
7 days after admission, yet eight of the 13 patients who
developed VAP in the control group reacquired another
one or two types of pathogens in the late period (> 7
days), while only one in the probiotic group experienced
such conditions (61.5% vs. 14.3%, P =0 . 0 7 ) .A sar e s u l t ,
more patients in the control group were infected by
more than two types of pathogens compared with the
probiotic group (76.9% vs. 14.3%, P = 0.017). Moreover,
the two events of urinary tract infection occurred in the
late period as well, presenting a higher late infection
rate related to the absence of probiotics (38.5% vs. 4%, P
= 0.002).
All patients received antibiotic prophylaxis, and no
significant difference was observed in terms of the days
of antibiotic treatment between groups. However,
patients in the control group were treated with signifi-
cantly more types of antibiotics (Table 1). The antibio-
tics primarily used were cefmetazole, imipenem, and
vancomycin.
There were no significant differences to the APACHE
II or SOFA scores at any time point, but the length of
ICU stay was significantly shorter among patients in the
probiotic group (Table 1). No significant difference was
found with regards to the 28-day mortality rate.
Adverse events
No adverse effects of probiotic therapy were observed
during the study period. No patients developed sepsis
related to Lactobacillus and bowel ischemia.
Discussion
The present study showed that the administration of
probiotics could adjust the Th1/Th2 imbalance induced
by severe TBI, and could result in a decreased infection
rate during the late period, decrease the use of antibio-
tics, and result in a shorter stay in the ICU.
Previous studies indicated that probiotic therapy could
reduce intestinal hyperpermeability, elevate IgA and IgG
concentrations, decrease CRP, IL-6 and lipopolysacchar-
ide levels in critically ill or multiple-injured patients
[20-23], and skew the Th1/Th2 balance toward Th1 in
allergic murine models and patients as well as antibio-
tic-treated mice by both in vitro and in vivo studies
[24-27]. Our current study was the first randomized
trial that investigated the effects of probiotics in severe
TBI patients with the Th1/Th2 balance as a primary
endpoint.
Literature has reported that the extent and duration of
the Th1 suppression in brain-injured patients has a
positive correlation with an increased risk of infectious
complications and poor outcomes [2,4]. An early and
long period of impaired cellular immune function, mani-
fested by sustained low levels of IFNg and high concen-
trations of IL-4 and IL-10, was shown in the present
study. However, patients who received probiotics
Table 1 Patient characteristics and clinical outcomes
Intention to treat P
value
Probiotic (n =
26)
Control (n =
26)
Age (years) 40.5 ± 13.0 40.8 ± 12.8 0.940
Gender (male/female) 19/7 21/5 0.510
Body mass index (kg/m
2) 22.3 ± 1.1 22.3 ± 1.4 0.841
Glasgow Coma Scale 6.31 ± 1.01 6.42 ± 1.03 0.689
Blood glucose (mmol/l) 8.0 ± 1.1 7.9 ± 1.5 0.830
Patients using pantoprazole 20 (76.9%) 19 (73.1%) 0.749
Patients receiving MV < 48
hours
15 (57.7%) 16 (61.5) 0.777
Patients receiving MV ≥ 48
hours
1 (3.8%) 3 (11.5%) 0.574
APACHE II score
Day 1 14.8 ± 3.6 14.3 ± 3.6 0.645
Day 4 14.2 ± 5.8 13.7 ± 5.5 0.753
Day 8 11.5 ± 6.4 12.8 ± 6.5 0.497
Day 15 9.2 ± 6.4 11.5 ± 7.9 0.305
Day 21 8.0 ± 7.7 9.9 ± 8.5 0.368
SOFA score
Day 1 6.5 ± 1.4 6.3 ± 1.4 0.679
Day 4 5.7 ± 2.9 5.9 ± 2.2 0.341
Day 8 4.6 ± 3.3 5.1 ± 2.8 0.369
Day 15 3.7 ± 3.5 4.9 ± 4.4 0.374
Day 21 3.5 ± 4.2 4.4 ± 4.7 0.454
Duration of antibiotic use
(days)
11.9 ± 4.9 14.1 ± 6.0 0.154
Types of antibiotics (n/day) 1.3 ± 0.5 1.7 ± 0.7 0.021
Length of ICU stay (days) 6.8 ± 3.8 10.7 ± 7.3 0.034
28-day mortality 3 (11.5%) 5 (19.2%) 0.701
Data presented as mean ± standard deviation or n (%). Significant differences
in bold. MV, mechanical ventilation; APACHE, Acute Physiologic Chronic
Health Evaluation; SOFA, Sequential Organ Failure Assessment.
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Page 5 of 10exhibited higher levels of IL-12 with a further Th2-to-
Th1 switch compared with the controls after 15 days of
treatment, and the differences were significantly demon-
strated by day 21. The underlying mechanisms were
unknown and not addressed in the current study, but
may be related to the considerable DCs that are present
in the gastrointestinal tract and play a critical role in the
polarization of Th0 cells to Th1 or Th2 subsets by
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Figure 2 Serum IL-12p70, IFNg, IL-4, and IL-10 concentrations. Mean ± standard deviation. *P < 0.05, compared with normal controls (NC).
#P < 0.05, compared with the probiotic group.
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Page 6 of 10secreting IL-12, in which Toll-like receptors may be
involved [28].
In vitro studies have suggested that probiotics could
improve the maturation of DCs and further skew T cells
to Th1 polarization [29,30]. However, such effects
appear to vary among strains and species. For example,
Lactobacillus reuteri upregulated surface mature makers
on DCs but inhibited the production of IL-12 [30]. The
probiotic cocktail VSL#3 - containing Lactobacillus
casei, Lactobacillus plantarum, Lactobacillus acidophi-
lus, L. delbrueckii bulgaricus, Bifidobacterium breve, B.
longum, Bifidobacterium infantis,a n dS. salivarius ther-
mophilus - induced the secretion of IL-10 by DCs from
blood and intestinal tissue and restrained the generation
of Th1 cells [31]. Probiotic effects thus cannot be gener-
alized and the characteristics of individual probiotic
strains need to be understood to pair them with specific
disease states or desired goals. The probiotics we chose
showed obvious Th1 polarization by in vitro and in vivo
studies [26].
There were decreased tendencies regarding the total
infections (34.6% vs. 57.7%, P = 0.095) and VAP (43.8%
vs. 68.4%, P = 0.182) among patients in the probiotic
group, but no significance was achieved. This could be
primarily explained by the small sample size involved in
o u rs t u d y .B a s e do nt h ed a t aw eo b t a i n e d ,a tl e a s t6 0
mechanically ventilated patients would be required in
each arm to obtain differences with regards to the inci-
dence of VAP, with an 80% power at a risk of 0.05. One
trial after the publication of the aforementioned two
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Figure 3 Serum IL-6 and C-reactive protein concentrations. Mean ± standard deviation. CRP, C-reactive protein. *P < 0.05, compared with
normal controls (NC).
#P < 0.05, compared with the probiotic group.
Table 2 Number and type of infections
Probiotic
group
Control
group
P
value
Type of infection
Ventilator-associated
pneumonia
7 (43.8%) 13 (68.4%) 0.182
Pneumonia
a 2 (20%) 1 (16.7%) 1.000
Urinary tract infection 0 2 (7.7%) 0.471
Wound infection 0 0
Bloodstream infection 0 0
Patients with infections 9 (34.6%) 15 (57.7%) 0.095
Patients with one infection 9 (34.6%) 14 (53.8%)
Patients with two
infections
0 1 (3.8%)
Data presented as n (%).
aInvolved patients were not mechanically ventilated.
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Page 7 of 10meta-analysis [10,11] involved 146 mechanically venti-
lated patients and showed significantly reduced VAP
and fewer days of antibiotics prescribed for VAP with
probiotic therapy [32]. However, another study failed to
demonstrate a significant decrease in VAP with the pre-
sence of probiotics, but a difference was found relating
to catheter-related bloodstream infections [33].
Our study showed no significant differences regarding
the days of antibiotics use, but patients in the probiotic
group were treated with fewer types of antibiotics. In
addition, we found in the late period (7 days following
admission) that fewer patients in the probiotic group
acquired or reacquired pathogens. A significantly lower
late infection rate was observed in the probiotic group
(4% vs. 38.5%, P = 0.002), which coincided with the
improved cellular immunity int h el a t ep e r i o d ,s u g g e s t -
ing a role for probiotics in inhibiting the invasion of
pathogenic bacteria and suppressing infections in the
severely brain-injured patient. Similar findings were
observed in previous reports by Knight and Fukushima.
In the study conducted by Knight and colleagues, a
decreased incidence of VAP was found (9% vs. 13%) in
the symbiotic group - which, however, exhibited a
slightly higher colonization rate by pathogens compared
with the control group [34]. In the other study, patients
who received probiotics demonstrated a significantly
lower infection rate and more improved immunity than
those of the control group but without any significant
changes in fecal microbiota between groups at any time
point [35]. One may thus postulate that probiotics may
act themselves mainly by enhancing the immunological
status.
CRP is an extremely sensitive marker of inflammation
that can differentiate the various stages of systemic
inflammatory response syndrome in the absence of an
infection. Combined with another important inflamma-
tory cytokine (IL-6), CRP correlates positively with ill-
ness severity and can be used to predict subsequent
organ dysfunction and mortality [36]. As was seen in
the previous studies [20-22], the present study also
demonstrated lower serum levels of CRP and IL-6 in the
probiotic group than those of the control group by days
15 and 21 (Figure 3). This may be partially attributable
to more patients in the control group acquiring infec-
tions during the late period.
A shorter length of ICU stay was observed with pro-
biotic therapy, but the APACHE II and SOFA scores as
well as the 28-day mortality rate revealed no significant
differences (Table 1). The small sample size may be one
main reason contributing to these results. Similar find-
ings were also illustrated in other studies [20,21], in
which 28 and 72 ICU patients were recruited in total,
and probiotics increased the serum levels of IgA and
IgG, and decreased the rate of VAP without significant
improvement of multiple organ dysfunction syndrome
scores and mortality rates.
Our study indicated that no adverse events were
linked to probiotic treatment as reported by Besselink
and colleagues [37]. A recent systematic review con-
cluded that the majority of probiotics can be safely used
in patients receiving nutritional support, as per the evi-
dence found in another 72 articles, including that of
Besselink and colleagues. Only three trials showed
increased complications among specific patients who
experienced transplant and pancreatitis, and two of the
three patients received probiotics through a postpyloric
tube [38].
The probiotics we chose for this study - B. longum, L.
bulgaricus,a n dS. thermophilus -a r ew e l lk n o w nf o r
their safety. The Bifidobacteria belong to the largest
anaerobic bacterial populations of the human gastroin-
testinal tract. In vitro studies showed that B. longum
was not only able to grow in 2% bovine bile, grow at pH
3.5, inhibit most intestinal pathogens, produce bacterio-
cin-like substances, and adhere to human epithelial
cells, but also showed no resistance to antibiotics [39].
In addition, by means of reducing the redox potential to
sufficient levels and manufacturing lactic acid, L. bulgar-
icus can provide a good environment for the growth of
B. longum [40].
Table 3 Isolated pathogens on tracheobronchial secretions cultures in patients with ventilator-associated pneumonia
Probiotic group (n = 16)
a Control group (n = 19)
b P value
Isolated pathogen
Pseudomonas aeruginosa 5 (31.3%) 9 (47.4%) 0.491
Staphylococcus aureus 2 (12.5%) 5 (26.3%) 0.415
Acinetobacter baumanii 2 (12.5%) 6 (31.6%) 0.244
Klebsiella pneumoniae 0 2 (10.5%) 0.489
Escherichia cloacae 0 4 (21.1%) 0.109
Yeast-like fungus 0 2 (10.5%) 0.489
Patients with VAP infected with ≥ 2 kinds of pathogens 1 (14.3%) 10 (76.9%) 0.017
Patients reacquired another pathogen 7 days after admission 1 (14.3%) 8 (61.5%) 0.07
Data presented as n (%). Significant differences in bold.
aSixteen patients in the probiotic group received mechanical ventilation.
bNineteen patients in the
control group received mechanical ventilation. VAP, ventilator-associated pneumonia.
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tions and should be considered a pilot study. The small
sample size and the single center studied, which carries
inherent biases related to some local practice habits,
limit the extrapolation of the results. Larger and multi-
center studies are further required to test the effect of
probiotics on these clinical outcomes. Our primary aim
was to evaluate the changes of Th1/Th2 cytokines, how-
ever, and the data we achieved confirmed the effective-
ness of probiotics and provided a basis for calculating
the number of patients needed in future studies. The
second limitation could be that the study was not dou-
ble-blinded and placebo-controlled, because probiotic
therapy must be prescribed by the physicians in charge
after randomization. Furthermore, probiotics are readily
available and may be prescribed by physicians to man-
age diarrhea in the research unit, so the investigator
must rigorously monitor the study period to avoid such
interference. As far as the absence of placebo is con-
cerned, the involved patients were all unconscious and
unaware of the trial. The routinely used semiquantitative
cultures of tracheal aspirates used in the hospital to
confirm a clinical diagnose of VAP may have been
another limitation, as this has reduced accuracy in com-
parison with quantitative results. However, quantitative
methods may not have been reliable in severely ill
patients receiving prior antibiotics, for they exhibited
markedly low sensitivity under these circumstances [41].
Conclusions
Our findings suggest that daily prophylactic administra-
tion of probiotics could attenuate the deviated Th1/Th2
response induced by severe TBI, which may contribute
to the decreased nosocomial infection rate, especially as
shown in the late period.
Key messages
￿ When administered enterally to severe traumatic
injury patients, probiotics improved cellular immune
function as illustrated by the Th2-to-Th1 switch in
the late period.
￿ Probiotic therapy appears to be an alternative way
to reduce the occurrence of nosocomial infections.
￿ Probiotics contribute to decreasing infections
mainly by enhancing the immunological status.
￿ Probiotics could be safely used in critically ill
patients.
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